NTLA Stock Recent News
NTLA LATEST HEADLINES
NEW YORK CITY, NY / ACCESS Newswire / April 12, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=142629&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / April 12, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ:NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2024 lead plaintiff deadline. SO WHAT: If you purchased Intellia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
NEW YORK, April 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of TransMedics Group, Inc. (NASDAQ: TMDX) between February 28, 2023 and January 10, 2025, both dates inclusive (the “Class Period”), of the important April 15, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.
NEW YORK CITY, NY / ACCESS Newswire / April 12, 2025 / Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Intellia To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Intellia between July 30, 2024 and January 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ:NTLA) and reminds investors of the April 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
NEW YORK, NY / ACCESS Newswire / April 11, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=142617&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / April 11, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=142582&wire=1 or contact Joseph E. Levi, Esq.
Investors can contact the law firm at no cost to learn more about recovering their losses
Investors can contact the law firm at no cost to learn more about recovering their losses
Investors can contact the law firm at no cost to learn more about recovering their losses Investors can contact the law firm at no cost to learn more about recovering their losses
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025. Intellia describes itself as a “leading clinical-stage gene editing company, focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.” For more information, submit a form, email attorney Phillip Kim,.